...UB-612 from United Biomedical Inc.’s COVAXX unit, which is in the process of merging with United Neuroscience...

...$2.8 billion. The United Biomedical Inc. subsidiary, which is in the process of merging with United Neuroscience...

...the merger of its two predecessor entities, United Neuroscience...
...the same vaccine platform for different purposes. United Neuroscience...
...enough early clinical data in Alzheimer’s, via United Neuroscience...

...hiring Ajay Verma as SVP, head of experimental medicine and neurology. He was CMO at United Neuroscience...

...medical journals. The double-blind Chinese study enrolled about 43 patients to receive UB-311 or placebo. United Neuroscience...
...β amyloid designed to induce high B cell specific responses while avoiding T cell inflammation. United Neuroscience...
...disease Endpoint: Safety and immunogenicity Status: Phase IIa data Milestone: NA Sandi Wong UBITh Amyloid-beta (UB-311) United Biomedical Inc. United Neuroscience Ltd. Beta...

...Neurodegenerative diseases company United Neuroscience Ltd. (Dublin, Ireland) hired Peter Powchik as its first EVP of R&D, effective...

...of patients in a Phase II study of AN-1792 developed meningoencephalitis. CMO Ajay Verma said United Neuroscience’s...
...complex manufacturing process. “The cost of goods is easier with vaccines,” he said. Last year, United Neuroscience...
...“United Neuroscience is well funded past the completion of the UB-311 Phase IIa trial.” COMPANY PROFILE United Neuroscience Ltd....

...Southwestern Medical Center (Dallas, Texas) will evaluate vaccine candidates based on the Endobody platform from United Neuroscience Ltd....
...postmortem tissue samples and preclinical models of neurodegenerative disease. The companies declined to provide details. United Neuroscience Ltd....
...of Texas Southwestern Medical Center, Dallas, Texas Business: Neurology Jaime De Leon University of Texas Southwestern Medical Center United Neuroscience Ltd....

...CNRS will characterize the candidates and evaluate their ability to treat PD and other synucleinopathies. United Neuroscience Ltd....
...Recherche Scientifique (CNRS), Paris, France Business: Neurology Shannon Lehnbeuter Centre National de la Recherche Scientifique (CNRS) Alpha synuclein (SNCA) United Neuroscience Ltd....

...trial of UB-311 to treat early to mild AD are expected in mid-2018. In 2014, United Neuroscience...
...Hauppauge, N.Y.) and received exclusive, worldwide rights to UB-311. United Biomedical Inc. , Hauppauge, N.Y. United Neuroscience...
...Endpoint: Safety and immunogenicity Status: Phase I data Milestone: Phase II data (mid-2018) Alicia Parker UB-311 United Biomedical Inc. United Neuroscience Ltd. Beta...